Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
Journal article
Zivanovic N. et al, (2023), Clin Transl Med, 13
Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.
Journal article
Hanumunthadu B. et al, (2023), BMJ Open, 13
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Journal article
Folegatti P. et al, (2020), LANCET, 396, 466 - 466
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Journal article
Jefferies K. et al, (2020), The Journal of infectious diseases
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
Journal article
Wildenbeest JG. et al, (2020), The Journal of infectious diseases
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
HODGSON S., (2020), The Lancet
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants
Internet publication
Valente Pinto M. et al, (2020)
Low Sensitivity of BinaxNOW RSV in Infants.
Journal article
Zuurbier RP. et al, (2020), The Journal of infectious diseases
Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13
Journal article
Kandasamy R. et al, (2019), Journal of Infectious Diseases
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.
Journal article
Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
Journal article
McQuaid F. et al, (2015), CMAJ, 187, E215 - E223
A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.
Journal article
Hamaluba M. et al, (2015), Medicine (Baltimore), 94
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
Journal article
McQuaid F. et al, (2014), Pediatr Infect Dis J, 33, 760 - 766
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
Journal article
Snape MD. et al, (2013), CMAJ, 185, E715 - E724
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
Journal article
Snape MD. et al, (2013), Pediatr Infect Dis J, 32, 1116 - 1121
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial
Journal article
Snape MD. et al, (2013), Pediatric Infectious Disease Journal, 32, 1116 - 1121
Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
Journal article
Khatami A. et al, (2011), Clin Vaccine Immunol, 18, 2038 - 2042